Walter Noordzij
dr.
In my profession as a nuclear medicine physician, I’m involved in both clinical and scientific applications of nuclear medicine and radiology modalities. My main interests include haematology, general oncology, radio-immunotherapy, and especially the implementation of new therapeutic strategies. Currently, I have a special interest in imaging post-transplant lymphoproliferative disease, as well as radio-immunotherapy in chemotherapy refractory (non)-Hodgkin’s lymphoma.
EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-022-05919-1
document
PURPOSE: Current European Association of Nuclear Medicine (EANM) Research Ltd. (EARL) guidelines for the standardisation of PET imaging developed for conventional systems have not yet been adjusted for long axial field-of-view (LAFOV) systems. In order to use the LAFOV Siemens Biograph Vision Quadra PET/CT (Siemens Healthineers, Knoxville, TN, USA) in multicentre research and harmonised clinical use, compliance to EARL specifications for 18F-FDG tumour imaging was explored in the current study. Additional tests at various locations throughout the LAFOV and the use of shorter scan durations were included. Furthermore,...
Joyce van Sluis, Johannes H van Snick, Adrienne H Brouwers, Walter Noordzij, Rudi A J O Dierckx, Ronald J H Borra, Riemer H J A Slart, Adriaan A Lammertsma, Andor W J M Glaudemans, Ronald Boellaard, Charalampos Tsoumpas
Digital PET Systems
Published in: Nuclear Medicine and Molecular Imaging
Access to document
10.1016/B978-0-12-822960-6.00131-9
document
In the past decades, the main development in positron emission tomography (PET) technology has been detector design, specifically the adoption of solid-state technology. Conventional photomultiplier tubes have been replaced by compact detector elements commonly referred to as silicon-photomultipliers (SiPMs). At present, there are three commercially available PET/CT systems equipped with SiPM-based detectors. These so-called “digital” PET/CT systems are the Philips Vereos PET/CT (Philips Healthcare), the Siemens Biograph Vision PET/CT (Siemens Healthineers), and the GE Discovery MI PET/CT (General Electric Healthcare). This chapter on digital PET describes the technical...
The integrated nuclear medicine and radiology residency program in the Netherlands: strengths and potential areas for improvement according to nuclear medicine physicians and radiologists
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-022-05699-8
document
PURPOSE: To evaluate the Dutch integrated nuclear medicine and radiology residency program from the perspective of nuclear medicine physicians and radiologists. METHODS: A survey was distributed among nuclear medicine physicians and radiologists in hospitals that participate in the Dutch integrated nuclear medicine and radiology training program. RESULTS: A total of 139 completed questionnaires were included. Nuclear medicine physicians (n = 36) assigned a mean score of 5.7 ± 2.0, and radiologists (n = 103) assigned a mean score of 6.5 ± 2.8 (on a 1-10 scale) to the success of the integrated training program in their...
Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
Published in: European Journal of Hybrid Imaging
Access to document
10.1186/s41824-022-00133-6
document
BACKGROUND: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor expression with 68Ga-DOTA somatostatin analogues is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). [18F]DOPA can detect additional lesions compared to [68Ga]DOTA-TOC. The aim of this study was to explore differences in tumour detection of both tracers and their relevance for selecting patients for PRRT. We retrospectively studied eight patients with NENs who underwent both [68Ga]DOTA-TOC and carbidopa-enhanced [18F]DOPA PET/CT, before first-time PRRT with [177Lu]DOTA-TATE. Tracer order was influenced due to stock availability or to...
Emile B Veenstra, Adrienne H Brouwers, Derk Jan A de Groot, Johannes Hofland, Annemiek M E Walenkamp, Tessa Brabander, Wouter T Zandee, Walter Noordzij
Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC
Published in: EJNMMI Research
Access to document
10.1186/s13550-022-00879-x
document
BACKGROUND: Post-therapy [90Y] PET/CT-based dosimetry is currently recommended to validate treatment planning as [99mTc] MAA SPECT/CT is often a poor predictor of subsequent actual [90Y] absorbed dose. Treatment planning software became available allowing 3D voxel dosimetry offering tumour-absorbed dose distributions and dose-volume histograms (DVH). We aim to assess dose-response effects in post-therapy [90Y] PET/CT dosimetry in SIRT-treated HCC patients for predicting overall and progression-free survival (OS and PFS) and four-month follow-up tumour response (mRECIST). Tumour-absorbed dose and mean percentage of the tumour volume (V) receiving ≥ 100, 150, 200, or...
Emile B Veenstra, Simeon J S Ruiter, Robbert J de Haas, Reinoud P H Bokkers, Koert P de Jong, Walter Noordzij